health pharma news today obesity drugs glp-1 today A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio New GLP-1 Pill Foundayo (Orforglipron)
Description
The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose
Moreover, individual metabolic characteristics, such as coexisting diabetes, obesity, or hepatic impairment, influence drug metabolism and response, underscoring the need for personalized treatment strategies
What helps with diarrhea could slow an already sluggish system
For some people, taking GLP-1s creates the mental space to be able to explore and address their food, nutrition and relationship with food
